Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus

Agnès Doreau; Alexandre Belot; Jérémy Bastid; Benjamin Riche; Marie-Claude Trescol-Biemont; Bruno Ranchin; Nicole Fabien; Pierre Cochat; Claire Pouteil-Noble; Pierre Trolliet; Isabelle Durieu; Jacques Tebib; Berhouz Kassai; Stéphane Ansieau; Alain Puisieux; Jean-François Eliaou; Nathalie Bonnefoy-Bérard

doi:10.1038/ni.1741

Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus

Nat Immunol. 2009 Jul;10(7):778-85. doi: 10.1038/ni.1741. Epub 2009 May 31.

Authors

Agnès Doreau¹, Alexandre Belot, Jérémy Bastid, Benjamin Riche, Marie-Claude Trescol-Biemont, Bruno Ranchin, Nicole Fabien, Pierre Cochat, Claire Pouteil-Noble, Pierre Trolliet, Isabelle Durieu, Jacques Tebib, Berhouz Kassai, Stéphane Ansieau, Alain Puisieux, Jean-François Eliaou, Nathalie Bonnefoy-Bérard

Affiliation

¹ Université de Lyon, Institut Fédératif de Recherche 128, Lyon, France.

PMID: 19483719
DOI: 10.1038/ni.1741

Abstract

Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that IL-17 alone or in combination with B cell-activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This effect was mediated mainly through the nuclear factor-kappaB-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance correlated with the disease severity of systemic lupus erythematosus.

Publication types

Research Support, Non-U.S. Gov't
Retracted Publication

MeSH terms

Antigens, CD19 / metabolism
Apoptosis / drug effects
B-Cell Activating Factor / pharmacology*
B-Lymphocytes / cytology
B-Lymphocytes / drug effects*
B-Lymphocytes / metabolism
Cell Differentiation / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Drug Synergism
Female
Humans
Immunoblotting
Immunoglobulins / metabolism
Interleukin-17 / blood*
Interleukin-17 / genetics
Interleukin-17 / pharmacology*
Lupus Erythematosus, Systemic / blood*
Lupus Erythematosus, Systemic / pathology
Male
Minor Histocompatibility Antigens
NF-kappa B / metabolism
Nuclear Proteins / genetics
Nuclear Proteins / metabolism
Proto-Oncogene Proteins c-bcl-2 / genetics
Proto-Oncogene Proteins c-bcl-2 / metabolism
Repressor Proteins / genetics
Repressor Proteins / metabolism
Reverse Transcriptase Polymerase Chain Reaction
Time Factors
Twist-Related Protein 1 / genetics
Twist-Related Protein 1 / metabolism

Substances

Antigens, CD19
B-Cell Activating Factor
BCL2-related protein A1
Immunoglobulins
Interleukin-17
Minor Histocompatibility Antigens
NF-kappa B
Nuclear Proteins
Proto-Oncogene Proteins c-bcl-2
Repressor Proteins
TWIST1 protein, human
TWIST2 protein, human
Twist-Related Protein 1